Position in REVB
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$387,889
+$40,472 QoQ
Shares Held
323,241
+197.7% QoQ
Ownership
8.11%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in REVB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARMISTICE CAPITAL, LLC holds $1,521,563,900 across 51 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
288,000 | $154,641,600 | |
| 2 | CYTK |
Cytokinetics Inc
|
1,201,342 | $102,342,324 | |
| 3 | INCY |
Incyte Corp
|
900,005 | $102,024,566 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
|
1,572,539 | $89,335,940 | |
| 5 | AGIO |
Agios Pharmaceuticals, Inc.
|
2,400,000 | $89,064,000 | |
| 6 | PTCT |
Ptc Therapeutics, Inc.
|
1,071,395 | $87,393,690 | |
| 7 | DYN |
Dyne Therapeutics, Inc.
|
3,087,226 | $68,567,289 | |
| 8 | IMVT |
Immunovant, Inc.
|
1,736,000 | $66,888,080 |
All Filings in REVB
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $387,889 | 323,241 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $347,417 | 434,272 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $113,600 | 80,000 | Shares | Sole | 2025-11-17 | |
| No filing history on record for this holder in this stock. | ||||||